- COVID-19
- Biosimilars
- Cataract Therapeutics
- DME
- Gene Therapy
- Workplace
- Ptosis
- Optic Relief
- Imaging
- Geographic Atrophy
- AMD
- Presbyopia
- Ocular Surface Disease
- Practice Management
- Pediatrics
- Surgery
- Therapeutics
- Optometry
- Retina
- Cataract
- Pharmacy
- IOL
- Dry Eye
- Understanding Antibiotic Resistance
- Refractive
- Cornea
- Glaucoma
- OCT
- Ocular Allergy
- Clinical Diagnosis
- Technology
Toric IOL gets FDA approval
The Tecnis toric 1-piece IOL (Abbott) has received FDA approval, and the company is launching the lens in the United States for treatment of cataract patients with pre-existing corneal astigmatism.
Abbott Park, IL-The Tecnis toric 1-piece IOL (Abbott) has received FDA approval, and the company is launching the lens in the United States for treatment of patients with cataract and pre-existing corneal astigmatism.
The toric 1-piece IOL remains very stable once inserted into the eye, and meets the new standard for toric IOL rotational stability, an important attribute of a toric IOL, as approved by the American National Standards Institute. In addition to providing astigmatism correction, the toric 1-piece lens minimizes spherical aberration to provide sharper distance vision for the patient.
“The . . . toric IOL decreases astigmatism while improving visual quality, with improved functional vision,” said Kevin Waltz, OD, MD, Eye Surgeons of Indiana, and clinical investigator for the Tecnis toric IOL. “Having implanted several . . . toric IOLs within clinical trials, I find it delivers excellent patient results.”
For more articles in this issue of Ophthalmology Times eReport, click here.
